{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T15:55:07Z","timestamp":1759334107983,"version":"build-2065373602"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,30]]},"DOI":"10.7759\/cureus.93549","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T12:17:37Z","timestamp":1759234657000},"source":"Crossref","is-referenced-by-count":0,"title":["Overall Diagnostic Efficiency of a Noninvasive Diagnostic Strategy Aimed at Early Detection of Advanced Liver Fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease Cases"],"prefix":"10.7759","author":[{"given":"Kunihiro","family":"Iwata","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoto","family":"Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuhiko","family":"Ogasawara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2023.11.005","article-title":"Natural history of metabolic dysfunction-associated steatotic liver disease","volume":"122","author":"Lekakis V","year":"2024","unstructured":"Lekakis V, Papatheodoridis GV. Natural history of metabolic dysfunction-associated steatotic liver disease. Eur J Intern Med. 2024, 122:3-10. 10.1016\/j.ejim.2023.11.005","journal-title":"Eur J Intern Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2023.06.013","article-title":"Aga clinical practice update on the role of noninvasive biomarkers in the evaluation and management of nonalcoholic fatty liver disease: expert review","volume":"165","author":"Wattacheril JJ","year":"2023","unstructured":"Wattacheril JJ, Abdelmalek MF, Lim JK, Sanyal AJ. Aga clinical practice update on the role of noninvasive biomarkers in the evaluation and management of nonalcoholic fatty liver disease: expert review. Gastroenterology. 2023, 165:1080-8. 10.1053\/j.gastro.2023.06.013","journal-title":"Gastroenterology"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-021-10143-4","article-title":"The epidemiology of NAFLD and lean NAFLD in Japan: a meta-analysis with individual and forecasting analysis, 1995-2040","volume":"15","author":"Ito T","year":"2021","unstructured":"Ito T, Ishigami M, Zou B, et al.. The epidemiology of NAFLD and lean NAFLD in Japan: a meta-analysis with individual and forecasting analysis, 1995-2040. Hepatol Int. 2021, 15:366-79. 10.1007\/s12072-021-10143-4","journal-title":"Hepatol Int"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.13947","article-title":"Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2014 to 2018 in Japan: a large-scale multicenter retrospective study","volume":"53","author":"Fujii H","year":"2023","unstructured":"Fujii H, Suzuki Y, Sawada K, et al.. Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2014 to 2018 in Japan: a large-scale multicenter retrospective study. Hepatol Res. 2023, 53:1059-72. 10.1111\/hepr.13947","journal-title":"Hepatol Res"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3138\/canlivj-2021-0019","article-title":"Liver biopsy complication rates in patients with non-alcoholic fatty liver disease","volume":"5","author":"Zhou F","year":"2022","unstructured":"Zhou F, Stueck A, McLeod M. Liver biopsy complication rates in patients with non-alcoholic fatty liver disease. Can Liver J. 2022, 5:106-12. 10.3138\/canlivj-2021-0019","journal-title":"Can Liver J"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/hep.32145","article-title":"Magnetic resonance elastography plus Fibrosis-4 versus FibroScan-aspartate aminotransferase in detection of candidates for pharmacological treatment of NASH-related fibrosis","volume":"75","author":"Tamaki N","year":"2022","unstructured":"Tamaki N, Imajo K, Sharpton S, et al.. Magnetic resonance elastography plus Fibrosis-4 versus FibroScan-aspartate aminotransferase in detection of candidates for pharmacological treatment of NASH-related fibrosis. Hepatology. 2022, 75:661-72. 10.1002\/hep.32145","journal-title":"Hepatology"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-021-01796-x","article-title":"Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis 2020","volume":"56","author":"Tokushige K","year":"2021","unstructured":"Tokushige K, Ikejima K, Ono M, et al.. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis 2020. J Gastroenterol. 2021, 56:951-63. 10.1007\/s00535-021-01796-x","journal-title":"J Gastroenterol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.13688","article-title":"Evidence-based clinical\u00a0practice guidelines for nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis 2020","volume":"51","author":"Tokushige K","year":"2021","unstructured":"Tokushige K, Ikejima K, Ono M, et al.. Evidence-based clinical\u00a0practice guidelines for nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis 2020. Hepatol Res. 2021, 51:1013-25. 10.1111\/hepr.13688","journal-title":"Hepatol Res"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/jgh3.12590","article-title":"Validation of a two-step approach combining serum biomarkers and liver stiffness measurement to predict advanced fibrosis","volume":"5","author":"Fujii H","year":"2021","unstructured":"Fujii H, Enomoto M, Fukumoto S, et al.. Validation of a two-step approach combining serum biomarkers and liver stiffness measurement to predict advanced fibrosis. JGH Open. 2021, 5:801-8. 10.1002\/jgh3.12590","journal-title":"JGH Open"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.15893","article-title":"Validation of magnetic resonance elastography plus fibrosis-4 for significant fibrosis in nonalcoholic fatty liver disease","volume":"37","author":"Inada K","year":"2022","unstructured":"Inada K, Tamaki N, Kurosaki M, et al.. Validation of magnetic resonance elastography plus fibrosis-4 for significant fibrosis in nonalcoholic fatty liver disease. J Gastroenterol Hepatol. 2022, 37:1726-31. 10.1111\/jgh.15893","journal-title":"J Gastroenterol Hepatol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.2957\/kanzo.65.186","article-title":"Importance of ALT levels of >30 in patients with","volume":"65","author":"Kawanaka M","year":"2024","unstructured":"Kawanaka M, Fujii H, Iwaki M, et al.. Importance of ALT levels of >30 in patients with. MASLD: Nara Declaration. 2024, 65:186-91. 10.2957\/kanzo.65.186","journal-title":"MASLD: Nara Declaration"},{"key":"ref12","article-title":"Meta-Analysis, Decision Analysis, and Cost-Effectiveness Analysis: Methods for Quantitative Synthesis in Medicine","author":"Petitti DB","year":"2000","unstructured":"Petitti DB. Meta-Analysis, Decision Analysis, and Cost-Effectiveness Analysis: Methods for Quantitative Synthesis in Medicine. Oxford University Press, New York; 2000."},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1105","article-title":"Progression of liver fibrosis is associated with non-liver-related mortality in patients with nonalcoholic fatty liver disease","volume":"1","author":"Tada T","year":"2017","unstructured":"Tada T, Kumada T, Toyoda H, Mizuno K, Sone Y, Akita T, Tanaka J. Progression of liver fibrosis is associated with non-liver-related mortality in patients with nonalcoholic fatty liver disease. Hepatol Commun. 2017, 1:899-910. 10.1002\/hep4.1105","journal-title":"Hepatol Commun"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2022.05.015","article-title":"Poor diagnostic efficacy of noninvasive tests for advanced fibrosis in obese or younger than 60 diabetic NAFLD patients","volume":"21","author":"Ito T","year":"2023","unstructured":"Ito T, Nguyen VH, Tanaka T, et al.. Poor diagnostic efficacy of noninvasive tests for advanced fibrosis in obese or younger than 60 diabetic NAFLD patients. Clin Gastroenterol Hepatol. 2023, 21:1013-1022.e6. 10.1016\/j.cgh.2022.05.015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000604","article-title":"National prevalence estimates for steatotic liver disease and subclassifications using consensus nomenclature","volume":"79","author":"Lee BP","year":"2024","unstructured":"Lee BP, Dodge JL, Terrault NA. National prevalence estimates for steatotic liver disease and subclassifications using consensus nomenclature. Hepatology. 2024, 79:666-73. 10.1097\/HEP.0000000000000604","journal-title":"Hepatology"},{"key":"ref16","article-title":"Epidemiology","author":"Gordis L","year":"2014","unstructured":"Gordis L. Epidemiology. Elsevier Saunders, Philadelphia, PA; 2014."},{"key":"ref17","article-title":"","author":"Sox H","year":"1989","unstructured":"Sox H, Stern S, Owens D, et al.. Assessment of Diagnostic Technology in Health Care Assessment of Diagnostic Technology in Health \uff11 Care: Rationale, Methods, Problems, and Directions: Monograph of the Council on Health Care Technology.  National Academies Press, Washington (DC); 1989."},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.2478\/jccm-2021-0022","article-title":"Accuracy of diagnostic tests","volume":"7","author":"Santini A","year":"2021","unstructured":"Santini A, Man A, Void\u0103zan S. Accuracy of diagnostic tests. J Crit Care Med (Targu Mures). 2021, 7:241-8. 10.2478\/jccm-2021-0022","journal-title":"J Crit Care Med (Targu Mures)"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1186\/1748-5908-6-62","article-title":"Application of GRADE: making evidence-based recommendations about diagnostic tests in clinical practice guidelines","volume":"6","author":"Hsu J","year":"2011","unstructured":"Hsu J, Bro\u017cek JL, Terracciano L, et al.. Application of GRADE: making evidence-based recommendations about diagnostic tests in clinical practice guidelines. Implement Sci. 2011, 6:62. 10.1186\/1748-5908-6-62","journal-title":"Implement Sci"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","year":"2024","unstructured":"EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024, 81.492-542. 10.1016\/j.jhep.2024.04.031","journal-title":"J Hepatol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-022-02290-1","article-title":"Distribution of FIB-4 index in the general population: analysis of 75,666 residents who underwent health checkups","volume":"22","author":"Sugiyama A","year":"2022","unstructured":"Sugiyama A, Kurisu A, E B, et al.. Distribution of FIB-4 index in the general population: analysis of 75,666 residents who underwent health checkups. BMC Gastroenterol. 2022, 22:241. 10.1186\/s12876-022-02290-1","journal-title":"BMC Gastroenterol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-22767-z","article-title":"A 3-step approach to predict advanced fibrosis in nonalcoholic fatty liver disease: impact on diagnosis, patient burden, and medical costs","volume":"12","author":"Kobayashi T","year":"2022","unstructured":"Kobayashi T, Ogawa Y, Shinoda S, et al.. A 3-step approach to predict advanced fibrosis in nonalcoholic fatty liver disease: impact on diagnosis, patient burden, and medical costs. Sci Rep. 2022, 12:18174. 10.1038\/s41598-022-22767-z","journal-title":"Sci Rep"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.14039","article-title":"Validation study of age-independent fibrosis score (Fibrosis-3 index) in patients with metabolic dysfunction-associated steatotic liver disease","volume":"54","author":"Nouso K","year":"2024","unstructured":"Nouso K, Kawanaka M, Fujii H, et al.. Validation study of age-independent fibrosis score (Fibrosis-3 index) in patients with metabolic dysfunction-associated steatotic liver disease. Hepatol Res. 2024, 54:912-20. 10.1111\/hepr.14039","journal-title":"Hepatol Res"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.13871","article-title":"Diagnostic accuracy of enhanced liver fibrosis test for nonalcoholic steatohepatitis-related fibrosis: multicenter study","volume":"53","author":"Seko Y","year":"2023","unstructured":"Seko Y, Takahashi H, Toyoda H, et al.. Diagnostic accuracy of enhanced liver fibrosis test for nonalcoholic steatohepatitis-related fibrosis: multicenter study. Hepatol Res. 2023, 53:312-21. 10.1111\/hepr.13871","journal-title":"Hepatol Res"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.13495","article-title":"Accuracy of the Enhanced Liver Fibrosis test, and combination of the Enhanced Liver Fibrosis and non-invasive tests for the diagnosis of advanced liver fibrosis in patients with non-alcoholic fatty liver disease","volume":"50","author":"Inadomi C","year":"2020","unstructured":"Inadomi C, Takahashi H, Ogawa Y, et al.. Accuracy of the Enhanced Liver Fibrosis test, and combination of the Enhanced Liver Fibrosis and non-invasive tests for the diagnosis of advanced liver fibrosis in patients with non-alcoholic fatty liver disease. Hepatol Res. 2020, 50:682-92. 10.1111\/hepr.13495","journal-title":"Hepatol Res"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-019-01626-1","article-title":"Diagnostic accuracy of combined biomarker measurements and vibration-controlled transient elastography (VCTE) for predicting fibrosis stage of non-alcoholic fatty liver disease","volume":"55","author":"Shima T","year":"2020","unstructured":"Shima T, Sakai K, Oya H, et al.. Diagnostic accuracy of combined biomarker measurements and vibration-controlled transient elastography (VCTE) for predicting fibrosis stage of non-alcoholic fatty liver disease. J Gastroenterol. 2020, 55:100-12. 10.1007\/s00535-019-01626-1","journal-title":"J Gastroenterol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1007\/s10396-023-01293-z","article-title":"Comparison of strain elastography and shear wave elastography in diagnosis of fibrosis in nonalcoholic fatty liver disease","volume":"50","author":"Ogino Y","year":"2023","unstructured":"Ogino Y, Wakui N, Nagai H, Matsuda T. Comparison of strain elastography and shear wave elastography in diagnosis of fibrosis in nonalcoholic fatty liver disease. J Med Ultrason. 2023, 50:187-95. 10.1007\/s10396-023-01293-z","journal-title":"J Med Ultrason"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2020.12.016","article-title":"Direct comparison of US and Mr elastography for staging liver fibrosis in patients with nonalcoholic fatty liver disease","volume":"20","author":"Imajo K","year":"2022","unstructured":"Imajo K, Honda Y, Kobayashi T, et al.. Direct comparison of US and Mr elastography for staging liver fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2022, 20:908-17. 10.1016\/j.cgh.2020.12.016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0249493","article-title":"Two-dimensional shear wave elastography and ultrasound-guided attenuation parameter for progressive non-alcoholic steatohepatitis","volume":"16","author":"Kuroda H","year":"2021","unstructured":"Kuroda H, Fujiwara Y, Abe T, et al.. Two-dimensional shear wave elastography and ultrasound-guided attenuation parameter for progressive non-alcoholic steatohepatitis. PLoS One. 2021, 16:e0249493. 10.1371\/journal.pone.0249493","journal-title":"PLoS One"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-46172-1","article-title":"Wisteria floribunda agglutinin-positive mac-2 binding protein as an age-independent fibrosis marker in nonalcoholic fatty liver disease","volume":"9","author":"Tamaki N","year":"2019","unstructured":"Tamaki N, Higuchi M, Kurosaki M, et al.. Wisteria floribunda agglutinin-positive mac-2 binding protein as an age-independent fibrosis marker in nonalcoholic fatty liver disease. Sci Rep. 2019, 9:10109. 10.1038\/s41598-019-46172-1","journal-title":"Sci Rep"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000262","article-title":"Cost-effectiveness of MRE versus VCTE in staging fibrosis for nonalcoholic fatty liver disease (NAFLD) patients with advanced fibrosis","volume":"77","author":"Sangha K","year":"2023","unstructured":"Sangha K, Chang ST, Cheung R, Deshpande VS. Cost-effectiveness of MRE versus VCTE in staging fibrosis for nonalcoholic fatty liver disease (NAFLD) patients with advanced fibrosis. Hepatology. 2023, 77:1702-11. 10.1097\/HEP.0000000000000262","journal-title":"Hepatology"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1111\/liv.15838","article-title":"Cost-effectiveness study of FIB-4 followed by transient elastography screening strategy for advanced hepatic fibrosis in a NAFLD at-risk population","volume":"44","author":"Park H","year":"2024","unstructured":"Park H, Yoon EL, Kim M, et al.. Cost-effectiveness study of FIB-4 followed by transient elastography screening strategy for advanced hepatic fibrosis in a NAFLD at-risk population. Liver Int. 2024, 44:944-54. 10.1111\/liv.15838","journal-title":"Liver Int"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000191","article-title":"Cost-effectiveness analysis of noninvasive tests to identify advanced fibrosis in non-alcoholic fatty liver disease","volume":"7","author":"Gruneau L","year":"2023","unstructured":"Gruneau L, Kechagias S, Sandstr\u00f6m P, Ekstedt M, Henriksson M. Cost-effectiveness analysis of noninvasive tests to identify advanced fibrosis in non-alcoholic fatty liver disease. Hepatol Commun. 2023, 7:10.1097\/HC9.0000000000000191","journal-title":"Hepatol Commun"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1002\/jmri.27703","article-title":"Assessment of imaging modalities against liver biopsy in nonalcoholic fatty liver disease: the Amsterdam NAFLD-NASH cohort","volume":"54","author":"Troelstra MA","year":"2021","unstructured":"Troelstra MA, Witjes JJ, van Dijk AM, et al.. Assessment of imaging modalities against liver biopsy in nonalcoholic fatty liver disease: the Amsterdam NAFLD-NASH cohort. J Magn Reson Imaging. 2021, 54:1937-49. 10.1002\/jmri.27703","journal-title":"J Magn Reson Imaging"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-023-10441-5","article-title":"A combination of non-invasive tests for the detection of significant fibrosis in patients with metabolic dysfunction-associated steatotic liver disease is not superior to magnetic resonance elastography alone","volume":"34","author":"Duman S","year":"2024","unstructured":"Duman S, Kuru D, Gumussoy M, et al.. A combination of non-invasive tests for the detection of significant fibrosis in patients with metabolic dysfunction-associated steatotic liver disease is not superior to magnetic resonance elastography alone. Eur Radiol. 2024, 34:3882-8. 10.1007\/s00330-023-10441-5","journal-title":"Eur Radiol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-021787","article-title":"Diagnostic accuracy of point shear wave elastography and transient elastography for staging hepatic fibrosis in patients with non-alcoholic fatty liver disease: a meta-analysis","volume":"8","author":"Jiang W","year":"2018","unstructured":"Jiang W, Huang S, Teng H, Wang P, Wu M, Zhou X, Ran H. Diagnostic accuracy of point shear wave elastography and transient elastography for staging hepatic fibrosis in patients with non-alcoholic fatty liver disease: a meta-analysis. BMJ Open. 2018, 8:e021787. 10.1136\/bmjopen-2018-021787","journal-title":"BMJ Open"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.14982\/rsmp.6.127","article-title":"Ethnic factors to be considered in multi-regional clinical trials (Article in Japanese)","volume":"6","author":"Koyama N","year":"2016","unstructured":"Koyama N, Yamamoto H. Ethnic factors to be considered in multi-regional clinical trials (Article in Japanese). J Regul Sci. 2016, 6:127-37. 10.14982\/rsmp.6.127","journal-title":"J Regul Sci"},{"key":"ref38","article-title":"Research on ethnic factors for promoting global drug development and pharmacovigilance in East Asia","volume":"141","author":"Sai K","year":"2023","unstructured":"Sai K. Research on ethnic factors for promoting global drug development and pharmacovigilance in East Asia. Bull Natl Inst Health Sci. 2023, 141:33-46.","journal-title":"Bull Natl Inst Health Sci"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/413979-overall-diagnostic-efficiency-of-a-noninvasive-diagnostic-strategy-aimed-at-early-detection-of-advanced-liver-fibrosis-in-metabolic-dysfunction-associated-steatotic-liver-disease-cases","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T12:17:38Z","timestamp":1759234658000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/413979-overall-diagnostic-efficiency-of-a-noninvasive-diagnostic-strategy-aimed-at-early-detection-of-advanced-liver-fibrosis-in-metabolic-dysfunction-associated-steatotic-liver-disease-cases"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,30]]},"references-count":38,"URL":"https:\/\/doi.org\/10.7759\/cureus.93549","relation":{},"ISSN":["2168-8184"],"issn-type":[{"type":"print","value":"2168-8184"}],"subject":[],"published":{"date-parts":[[2025,9,30]]}}}